Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, to deliver the 5th in VHIO´s prestigious series of VHIO Meet the Editors talks:
Cancer Cell and the Cancer Research Community
Related Posts
Josep Tabernero listed among the Highly Cited Researchers 2016: representing some of the world´s most influential scientific minds
In the recently announced Highly Cited Researcher listing 2016 by Clarivate Analytics – formerly the IP & Science business of…
21 Nov 2016
Sponsored Walking for Breast Cancer Research at VHIO: El Paseíco de la Mama once again surpasses all expectations
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
10 Jul 2014
Coming to VHIO 07-09 November: 2013 International Symposium on Progress Towards Individualized Cancer Treatments
Progress Towards Individualized Cancer Treatments 07 – 09 November 2013, marks the 17th International Symposium in the annual series of…
10 Sep 2013
VHIO´s Javier Cortes comments: Two Anti-HER2 Antibodies Better than One
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
Co-author Javier Cortés, Principle Investigator of VHIO´s Breast Cancer and Melanoma Group, describes the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) randomized trial, the importance and implications of the findings, as well as signposts future directions.
29 Dec 2011
Academy recognition of VHIO´s Director, Josep Tabernero, for his exceptional leadership and contribution to medical oncology, cancer science, and patient care
Announced this week, Josep Tabernero, Director of VHIO, Head of the Medical Oncology Service of the Vall d´Hebron University Hospital…
16 Feb 2017
Latest ESMO study reveals alarming disparities in availability and accessibility of anti-cancer therapies across Europe
Recently published as a Special Article in the flagship journal of the European Society of Medical Oncology (ESMO), Annals of…
05 Aug 2016
Studies Report New Findings on Treatment Options for Mesothelioma
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
30 Sep 2014
Josep Tabernero: 1 of the 11 Catalonia-based candidates for DIARIO MEDICO´s Top 25 ambassadors of biomedicine and healthcare in Spain – VOTING NOW OPEN
In celebration of its 25th Anniversary, DIARIO MEDICO – one of Spain´s leading medical periodicals, has just opened a poll…
04 Jul 2017
The New England Journal of Medicine coming to town: register now to attend the next VHIO Meet the Editors
VHIO Meet the Editors with The New England Journal of Medicine: Monday 14 May 2012
The New England Journal of Medicine´s Bette Phimister, Deputy Editor, will join us to deliver the next in the prestigious series of VHIO Meet the Editors talks:
Publishing Advances in Cancer Research
Bette Phimister will review progress and pitfalls in cancer research and issues concerning its publication, with a focus on targeted therapies and an eye to future developments.
13 Mar 2012
The European Cancer Patient’s Bill of Rights: A Catalyst for Change addressing inequalities in cancer in Europe
4th February, 2014, Strasbourg, France. A unique group of patient advocacy organisations, healthcare leaders (including two former health ministers and…
04 Feb 2014
The molecular mechanism behind elevated TGF-beta levels in the most aggressive brain tumor revealed
Latest research from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, recently published in the prestigious journal Cancer Discovery,…
08 Sep 2014
Novel bispecific agent as mono or in combo with paired immunotherapy promises increased therapeutic efficacy against metastatic colorectal cancer
Novel bispecific antibody that simultaneously binds to the carcinoembryonic antigen (CEA) and lymphocytes triggers immune response in patients with metastatic…
05 Jun 2017
VHIO´s Enriqueta Felip: recipient of the recently launched ESMO Women for Oncology Award
Source: The European Society for Medical Oncology (ESMO) Lugano, Switzerland, 27 August 2015 — The European Society for Medical Oncology…
01 Sep 2015
Joan Seoane awarded for exceptional contribution to translational cancer science and medicine
Barcelona, 28 January 2015. Today marks an important date in the diary for Joan Seoane, Director of Translational Research at…
28 Jan 2015
